The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / U.S. Senate Committee Advances Azar Nomination as Health Secretary

U.S. Senate Committee Advances Azar Nomination as Health Secretary

January 18, 2018 • By Reuters Staff

  • Tweet
  • Email
Print-Friendly Version / Save PDF

WASHINGTON (Reuters)—A U.S. Senate committee on Wednesday voted to move forward the nomination of Alex Azar, a former drug industry executive and lobbyist whom President Donald Trump has tapped to be the next secretary of Health and Human Services.

You Might Also Like
  • U.S. Senate Votes to Confirm Azar as Health Secretary
  • Trump to Tap Ex-Pharma Executive Azar as U.S. Health Secretary
  • Health Secretary Nominee Indicates Support for Medicaid Overhaul
Also By This Author
  • CVS Rolls Out New Tool to Combat Rising Drug Prices

The Senate Finance Committee voted 15-12 to advance Azar’s nomination, with all but one Democrat opposing. To receive final confirmation Azar will have to receive a majority vote in the 100-seat Senate, which Republicans control with 51 seats.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Among other issues, Azar would be charged with overseeing the Trump administration’s response to the opioid epidemic, and its efforts to weaken the Affordable Care Act, former Democratic President Barack Obama’s signature domestic policy achievement, commonly called Obamacare.

Azar spent about a decade at U.S. pharmaceutical firm Eli Lilly & Co, including five years as president of its U.S. unit. He left the company in 2017.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

During a Senate hearing last week, Democrats questioned how seriously he would work to make prescription drugs more affordable – an issue that Trump has repeatedly promised to address – and pointed to a handful of Lilly drugs whose prices more than doubled under Azar’s watch.

“Mr Azar could not provide a single example of when his company lowered prices,” said Senator Ron Wyden, the top ranking Democrat on the Senate Finance Committee. “I have no confidence that he will take a different approach to these key health care policies than his predecessor took.”

Trump’s first health secretary, former U.S. Representative Tom Price, resigned in September amid a furor over his use of expensive taxpayer-funded private charter jets for government travel.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Republicans said Azar, who also served as general counsel and deputy secretary for Health and Human Services under former Republican President George W. Bush, had the right experience to run the agency.

“By any objective account, Mr Azar is very well qualified for this important position,” said Senator Orrin Hatch, the top-ranking Republican on the committee.

 

Filed Under: Legislation & Advocacy Tagged With: nomination of Alex Azar, secretary of Health and Human Services, U.S. Senate Finance Committee

You Might Also Like:
  • U.S. Senate Votes to Confirm Azar as Health Secretary
  • Trump to Tap Ex-Pharma Executive Azar as U.S. Health Secretary
  • Health Secretary Nominee Indicates Support for Medicaid Overhaul
  • U.S. Senate Confirms Rep. Price as Health Secretary

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)